Last reviewed 2026-04-20 · How we verify

Nepafenac 0.3%

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Intraocular pressure increased
• Headache
• Blood glucose increased
• Anterior chamber inflammation
• Eye pain
• Posterior capsule opacification
• Urinary tract infection
• Conjunctival cyst
• Corneal oedema
• Macular oedema
• Vitreous detachment
• Vomiting

Key clinical trials

• The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
• Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
• Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension (PHASE3)
• Post Intravitreal Injection Topical NSAID vs. Patching (PHASE4)
• Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial (PHASE4)
• Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo (NA)
• Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (NA)
• PGE2 Levels in Patient Treated With NSAIDs (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nepafenac 0.3% CI brief — competitive landscape report
• Nepafenac 0.3% updates RSS · CI watch RSS
• Intuor Technologies, Inc. portfolio CI